CureVac N.V.




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-22 pm EDT 5-day change 1st Jan Change
3.79 USD +3.27% Intraday chart for CureVac N.V. +5.28% -9.98%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
CureVac Notes New Court Trial Timeline for Patent Cases Against Pfizer, BioNTech MT
CureVac Provides Trial Dates for Patent Litigation Against Pfizer, BioNTech MT
Health Stocks Slip in Risk-On Trade -- Health Care Roundup DJ
Sector Update: Health Care Stocks Fall in Afternoon Trading MT
Sector Update: Health Care MT
European Equities Close Higher in Wednesday Trading; Euro Area Growth Slows to 3-Month Low MT
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday MT
Looming Holiday Break Stifles US Equity Futures Pre-Bell MT
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of Economic Data Deluge MT
GSK to Buy COVID-19, Flu Vaccine Rights From CureVac for $1.56 Billion MT
Top Premarket Gainers MT
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion -- 2nd Update DJ
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update DJ
CureVac Enters Into New Licensing Agreement With GSK; to Implement 'Significant' Restructuring; Shares Rise Pre-Bell MT
GSK, CureVac Expand Licensing Agreement DJ
Keywords Studios agrees takeover by EQT AN
GSK and CureVac to Restructure Collaboration into New Licensing Agreement CI
GSK Signs New Licensing Deal With CureVac for Influenza, Covid-19 Vaccines MT
Gsk PLC - Gsk And Curevac Collaboration Restructured RE
CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board CI
CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate MT
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CI
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CUREVAC : Significant cash drain in the Q1 Alphavalue
Chart CureVac N.V.
More charts
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
3.482 EUR
Average target price
7.017 EUR
Spread / Average Target